TITLE

Prognostic and predictive factors in a randomized phase III trial comparing cisplatin–pemetrexed versus cisplatin–gemcitabine in advanced non-small-cell lung cancer

AUTHOR(S)
Syrigos, K. N.; Vansteenkiste, J.; Parikh, P.; von Pawel, J.; Manegold, C.; Martins, R. G.; Simms, L.; Sugarman, K. P.; Visseren-Grul, C.; Scagliotti, G. V.
PUB. DATE
March 2010
SOURCE
Annals of Oncology;Mar2010, Vol. 21 Issue 3, p556
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background: Baseline patient and disease characteristics are investigated in non-small-cell lung cancer (NSCLC) in an effort to predict response to treatment and optimize patients’ outcomes. Histology has recently been identified in multiple NSCLC phase III trials as a predictive factor for survival in patients receiving pemetrexed regimens.
ACCESSION #
48732927

 

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics